FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - January 7, 2026 136 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma 2026 ESMO Breast Cancer Award Recipient Announced Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type MOST POPULAR RNF43 Mutations Warrant Further Validation for Potential to Prioritise Anti-EGFR/BRAF Combinations... September 20, 2022 Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients... December 9, 2024 Cincinnati Police Are Wearing Pink Badges For Breast Cancer Awareness September 24, 2019 Sister Is There To Comfort Her Little Brother As He Battles... September 10, 2019 Load more HOT NEWS Benefit of Adjuvant Capecitabine After Curative Resection of Biliary Tract Cancer... Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma Nirogacestat Shows Significant Benefit in Patients with Progressing Desmoid Tumours Dormant Tumor Cells Can Be Sensitized to Chemotherapy
